Kent R Van Kampen
Veterinary in Birmingham, AL
License number
Utah 108609-8910
Issued Date
Jan 1, 1910
Expiration Date
Dec 31, 1988
Category
Veterinarian
Type
Veterinary Controlled Substance (Schedule 2-5)
Address
Address
Birmingham, AL
Professional information
Treatment Of Dermal Tumors, Warts, And Viral Infections Of The Respiratory Tract In Humans Using Heat-Killed P. Acnes
US Patent:
6726913, Apr 27, 2004
Filed:
Oct 13, 2000
Appl. No.:
09/689621
Inventors:
Kent R. Van Kampen - Hoover AL
Bobby G. Edwards - Salado TX
Bobby G. Edwards - Salado TX
Assignee:
The Van Kampen Group, Inc. - Hoover AL
International Classification:
A61K 4500
US Classification:
4242821, 424 934, 4241841, 4352521
Abstract:
Heat-killed, terminally sterilized saline suspensions of and are effective in treating viral infections of the respiratory tract in humans, and to induce the regression of dermal tumors and warts in humans. The potency of a saline suspension of heat-killed, terminally sterilized saline suspension of ( ) was demonstrated through a laboratory animal challenge model. The product is administered orally for the purpose of preventing or treating viral infections of the respiratory tract in man. The preparation is intralesionally administered into dermal tumors, warts such as plantar warts, or other warts in people caused by the human papilloma virus, to cause regression of such dermal tumors and warts. The subcutaneous route of administration of the product causes a systemic reaction that causes long-term warts to completely regress. Anesthetics such as Lidocaine may be added to the product to prevent pain upon injection of this immune modulating preparation, while retaining the potency of the product.
Noninvasive Genetic Immunization, Expression Products Therefrom And Uses Thereof
US Patent:
6348450, Feb 19, 2002
Filed:
May 3, 2000
Appl. No.:
09/563826
Inventors:
Donald H. Marks - Rockaway NJ
David T. Curiel - Birmingham AL
Zhongkai Shi - Birmingham AL
Kent Rigby van Kampen - Hoover AL
David T. Curiel - Birmingham AL
Zhongkai Shi - Birmingham AL
Kent Rigby van Kampen - Hoover AL
Assignee:
The UAB Research Foundation - Birmingham AL
International Classification:
A61K 4800
US Classification:
514 44, 424 9321, 4353201, 435375
Abstract:
Disclosed and claimed are methods of non-invasive genetic immunization in an animal and/or methods of inducing a systemic immune or therapeutic response in an animal, products therefrom and uses for the methods and products therefrom. The methods can include contacting skin of the animal with a vector in an amount effective to induce the systemic immune or therapeutic response in the animal. The vector can include and express an exogenous nucleic acid molecule encoding an epitope or gene product of interest. The systemic immune response can be to or from the epitope or gene product. The nucleic acid molecule can encode an epitope of interest and/or an antigen of interest and/or a nucleic acid molecule that stimulates and/or modulates an immunological response and/or stimulates and/or modulates expression, e. g. , transcription and/or translation, such as transcription and/or translation of an endogenous and/or exogenous nucleic acid molecule; e. g. , one or more of influenza hemagglutinin, influenza nuclear protein, tetanus toxin C-fragment, anthrax protective antigen, HIV gp 120, human carcinoembryonic antigen, and/or a therapeutic, an immunomodulatory gene, such as co-stimulatory gene and/or a cytokine gene.
System For Rapid Production Of High-Titer And Replication-Competent Adenovirus-Free Recombinant Adenovirus Vectors
US Patent:
2009017, Jul 9, 2009
Filed:
Nov 21, 2007
Appl. No.:
11/943901
Inventors:
Jianfeng Zhang - Birmingham AL, US
Kent R. Van Kampen - Birmingham AL, US
Kent R. Van Kampen - Birmingham AL, US
International Classification:
A61K 39/12, C12N 15/63, C12N 15/74, A61K 35/76, C12N 15/87, C12N 1/20
US Classification:
4241991, 4353201, 435477, 435489, 424 932, 435466, 4352528
Abstract:
The present invention relates generally to the fields of gene therapy, immunology, and vaccine technology. More specifically, the invention relates to a novel system that can rapidly generate high titers of adenovirus vectors that are free of replication-competent adenovirus (RCA). Also provided are methods of generating these RCA-free adenoviral vectors, immunogenic or vaccine compositions comprising these RCA-free adenovirus vectors, methods of expressing a heterologous nucleic acid of interest in these adenovirus vectors and methods of eliciting immunogenic responses using these adenovirus vectors.
Immunization Of Avians By Administration Of Non-Replicating Vectored Vaccines
US Patent:
2014003, Feb 6, 2014
Filed:
Sep 6, 2013
Appl. No.:
14/020024
Inventors:
Kent R. Van Kampen - Birmingham AL, US
Harold Toro - Auburn AL, US
Harold Toro - Auburn AL, US
International Classification:
A61K 39/145
US Classification:
4241991, 435 693
Abstract:
The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians. The invention also provides methods of introducing and expressing an avian immunogen in avian subjects, including avian embryos, as well as methods of eliciting an immunogenic response in avian subjects to avian immunogens.
Immunization Of Avians By Mucosal Administration Of Non-Replicating Vectored Vaccines
US Patent:
2011026, Nov 3, 2011
Filed:
Mar 25, 2011
Appl. No.:
13/071787
Inventors:
Haroldo Toro - Auburn AL, US
Kent R. Van Kampen - Hoover AL, US
Kent R. Van Kampen - Hoover AL, US
International Classification:
A61K 39/145, A61K 39/235, A61K 39/255, A61K 39/215, A61K 39/15, A61K 39/275, A61K 39/17, A61K 39/21, A61K 39/29, A61P 37/04, A61P 31/12, A61P 31/16, A61P 31/14, A61P 31/22, B65D 83/14, A61K 39/00
US Classification:
4242051, 4241841, 4242331, 4242091, 4242291, 4242221, 4242151, 4242321, 4242141, 4242071, 4242251, 222635
Abstract:
The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to mucosal administration via aerosol spray to avians of immunogenic and vaccine compositions, including those comprising recombinant human adenovirus vectors for delivery of genes encoding avian immunogens or antigens, such as genes encoding avian influenza virus. The invention also provides methods and apparatus for use in such administration.